Four-week dosing now approved in all Imfinzi indications, reducing medical visits and improving patient convenience

Attachments

  • Original document
  • Permalink

Disclaimer

AstraZeneca plc published this content on 20 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 November 2020 07:08:02 UTC